Advertisement
Advertisement
ASND
Ascendis Pharma A/S - ADR
221.91
USDSponsored
+4.53
+2.09%
Feb 06, 15:59 UTC -5
Closed
After-Market
222.62
+0.70
+0.32%
ASND Earnings Reports
Positive Surprise Ratio
ASND beat 16 of 40 last estimates.
40%
Next Report
Next Week
Date of Next Report
Feb 10, 2026
Estimate for Q4 25 (Revenue/ EPS)
$251.23M
/-$0.03
Implied change from Q3 25 (Revenue/ EPS)
+17.60%
/-97.00%
Implied change from Q4 24 (Revenue/ EPS)
+44.46%
/-95.31%
Ascendis Pharma A/S - ADR earnings per share and revenue
On Nov 12, 2025, ASND reported earnings of -1.00 USD per share (EPS) for Q3 25, missing the estimate of -0.22 USD, resulting in a -345.63% surprise. Revenue reached 213.63 million, compared to an expected 218.08 million, with a -2.04% difference. The market reacted with a +3.63% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 17 analysts forecast an EPS of -0.03 USD, with revenue projected to reach 251.23 million USD, implying an decrease of -97.00% EPS, and increase of 17.60% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Amgen Inc
Report Date
Feb 03, 2026 For Q4 25
Estimate
$4.82
Actual
$5.29
Surprise
+9.56%
Bristol-Myers Squibb Co.
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.12
Actual
$1.26
Surprise
+11.88%
GSK plc - ADR
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.23
Actual
$0.49
Surprise
+111.36%
Biogen Inc. Common Stock
Report Date
Feb 06, 2026 For Q4 25
Estimate
$1.62
Actual
$1.99
Surprise
+22.39%
Illumina Inc
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.24
Actual
$1.35
Surprise
+8.01%
QIAGEN N.V.
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.64
Actual
$0.62
Surprise
-3.32%
Arrowhead Research Corporation
Report Date
Feb 05, 2026 For Q1 26
Estimate
$0.25
Actual
$0.22
Surprise
-14.76%
Bio-Techne Corp.
Report Date
Feb 04, 2026 For Q2 26
Estimate
$0.44
Actual
$0.46
Surprise
+3.95%
Immunovant, Inc. Common Stock
Report Date
Feb 06, 2026 For Q3 26
Estimate
-$0.72
Actual
-$0.61
Surprise
+16.27%
Adaptive Biotechnologies Corporation Common Stock
Report Date
Feb 05, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.09
Surprise
+51.33%
FAQ
What were Ascendis Pharma A/S - ADR's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Ascendis Pharma A/S - ADR reported EPS of -$1.00, missing estimates by -345.63%, and revenue of $213.63M, -2.04% below expectations.
How did the market react to Ascendis Pharma A/S - ADR's Q3 2025 earnings?
The stock price moved up 3.63%, changed from $199.22 before the earnings release to $206.45 the day after.
When is Ascendis Pharma A/S - ADR expected to report next?
The next earning report is scheduled for Feb 10, 2026.
What are the forecasts for Ascendis Pharma A/S - ADR's next earnings report?
Based on 17
analysts, Ascendis Pharma A/S - ADR is expected to report EPS of -$0.03 and revenue of $251.23M for Q4 2025.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement